At-home self-injection therapy -- breakthrough convenience and efficacy. A clinical-grade self-injection drug delivery device for inflamed skin lesions, scaled through a telemedicine technology platform.
Series B 2025: In total $22M round on $75M Post. Split in two tranches of $15M on $35M pre and $7M on $68 pre Foresite doing $12M with Polaris and Atomic doing the rest" Series A: We purchased 2,560,819 new Series A-1 Shares and our CV converted to 2,648,939 shares. SH committed $200K, via StoryHouse Fund I, at a $15M valuation, in a $6M round, alongside Foresight Capital, Polaris Partners, Atomic Ventures, FORM Life Ventures, Myelin Ventures.
RAW NOTES: \- 1 month out for feedback from FDA; this is most important next milestone \- Confirmed investment and advisorship from significant strategic advisor; Rick is focused on bringing on some individuals like this given the new clinical direction of the business in advance of the Series A \-...
Source: Meeting Notes recp8Qgym2SpZuXtt
RAW NOTES: \- Getting the data back on the clinical data; 40 people, seeing identical outcomes from Dermatheory versus derm use \- Still got to get the white papers and publish it, but as far as getting raw data and something they can talk about \- He made an offer here and will likely make this...
Source: Meeting Notes recn7kccowN7OXqob
General • Working through clinical trials. Within 48 hours has been able to show significant improvements in patients. • They've been getting their clinical trial devices built • They've locked down second-gen design of the hardware. One feature he's excited about is that now the device will only...
Source: Meeting Notes recyp7BVoaHfMZqp5